NIH Study Reveals Critical Role of Fungi in Shaping Newborn Immunity and Metabolism
Published in Science, the study shows that fungi, particularly Candida dubliniensis, play a key role in early development of pancreatic beta cells. This process is mediated by macrophages and is critical for establishing lifelong healthy metabolism.
As someone who has spent years consulting biotech startups at the intersection of the microbiome and metabolic health, I read the news about Jennifer Hampton Hill and June Round's work with a very particular emotion. This is not just a paper in Science. It is the final chord in a years-long symphony where bacteria have long played the lead role, while fungi stood modestly in the chorus's shadow. Now the solo passes to them, and it overturns the entire paradigm of preventive endocrinology.
[The Gist]: What's Really Happening
Professor June Round's group at the University of Utah (supported by NIH through ORIP, NCCIH, NICHD, and NIDDK) uncovered a mechanism that most immunologists have missed for decades. It's not just that the fungus Candida dubliniensis helps pancreatic beta cells proliferate. It's about a strict temporal window.
The researchers proved that there is a critical 10-day window before weaning when resident microbes must be present in the gut to establish normal beta cell mass. If this window is missed due to lack of microbiota (as in germ-free mice) or due to antibiotics and antifungals, the pancreas develops inadequately. This is not a temporary glitch—it's a lifelong metabolic sentence.
The most elegant part is the role of macrophages. The fungus does not work directly with pancreatic cells. Components of the C. dubliniensis cell wall stimulate macrophage migration into the islets of Langerhans. Macrophages act as foremen, managing beta cell proliferation. Eliminate macrophages, and the fungus becomes useless. This explains why fecal samples from human infants aged 7–12 months strongly stimulated mouse beta cell growth, while samples from other age groups did not.
Timeline and Context
The publication in March 2025 (print edition March 7, PMID: 40048508) was the result of systematic work on microbiota ablation and restoration. The scientists methodically ruled out factors: they compared germ-free mice with conventional ones, then applied antibiotics and antifungals separately to understand that both bacteria and fungi affect beta cells.
Then came the most important phase—cross-transplantation of communities. The researchers identified specific taxa: the bacteria Escherichia coli, Enterococcus gallinarum, and the fungus Candida dubliniensis were sufficient to stimulate postnatal beta cell expansion in mice. RNA sequencing confirmed that C. dubliniensis is particularly effective at attracting macrophages. The finale was a test on adult animals with diabetes—the fungus not only reduced disease severity but also promoted beta cell recovery after ablation.
Who Wins and Who Loses
The next-generation probiotic segment wins. It's no longer about faceless "billions of lactobacilli." Companies that first create a stable formulation of C. dubliniensis for neonatal correction will have a product with lifelong value. The stakes: prevention of type 1 diabetes, a treatment market valued at $25 billion USD per year.
Pediatric endocrinologists win. They gain a window of opportunity at 7–12 months for screening and microbial intervention. If a child's stool analysis shows absence of C. dubliniensis at that age, the doctor can prescribe targeted fungal administration. This is a risk biomarker that didn't exist before.
The industry of aggressive antifungal treatment in infants loses. Pediatricians often prescribe antifungals for thrush or persistent diaper rash in the first year of life. Now each such prescription risks becoming the subject of future lawsuits: parents of a child with diabetes could link the disease to a "missed window." Round and her team directly showed that antifungals disrupt beta cell development.
A hidden loser: broad-spectrum antibiotic manufacturers. The study confirms the old hypothesis that early antibiotic use correlates with diabetes, but now a specific molecular mechanism is established. This gives FDA and EMA regulators arguments to tighten antibiotic prescribing guidelines for infants.
What the Media Isn't Saying
Most outlets enthusiastically write about "fungi saving from diabetes," but omit a troubling signal hidden in the methodology. The effect works only in a very narrow time window—10 days before weaning. If a mother gives her child antibiotics or antifungals precisely during this period, the window closes forever.
The most uncomfortable insider nuance is vertical transmission of the fungus. Candida dubliniensis often colonizes infants during passage through the birth canal and through breastfeeding. Cesarean section and formula feeding instead of breast milk may mean the child never encounters the right fungus at the critical moment. This raises a complex ethical question: should we routinely administer live fungi to at-risk infants? There is no answer, but the insurance cost of one such decision in case of error could be millions of USD.
Another nuance everyone missed: components of the C. dubliniensis cell wall are critical for signaling. This means that heat-killed fungus may not work. A live microorganism with an intact cell wall is needed. Transport, storage, and standardization of such a product is a logistical nightmare costing tens of millions of EUR, which startups haven't even considered yet.
Forecast: Next 30 Days and 90 Days
30 days. June Round's group will start receiving requests from major diabetes centers (Joslin Diabetes Center, Barbara Davis Center) for collaborations to test the hypothesis in human cohorts. We won't see loud press releases—a quiet collection of fecal samples from infants aged 6–12 months for prospective studies will begin.
Lawyers will also become active. Parent groups of children with type 1 diabetes who received antibiotics in the first year of life will start consulting about the possibility of class-action lawsuits against pharmaceutical companies. Compensation amounts could be in the range of $500 million USD.
90 days. Startups from Y Combinator and Flagship Pioneering will announce live biotherapeutic products based on C. dubliniensis. The first to market will not be preventive but therapeutic protocols for adults: the study showed that the fungus promotes beta cell recovery after ablation in adult animals. If confirmed in humans, we will have the first disease-modifying drug for patients with residual pancreatic function, and that will be a market of $18 billion EUR.
Finally, the FDA will issue new guidance on clinical trials for pediatric probiotics, requiring specific tests for effects on beta cells. This will slow the supplement market for several years but will separate real drugs from placebos. And all thanks to one fungus that quietly lived in infant intestines while we spent billions fighting its pathogenic relatives.
— Editorial Team
